Literature DB >> 18607000

Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.

Eric A Murphy1, Bharat K Majeti, Leo A Barnes, Milan Makale, Sara M Weis, Kimberly Lutu-Fuga, Wolfgang Wrasidlo, David A Cheresh.   

Abstract

Integrin alphanubeta3 is found on a subset of tumor blood vessels where it is associated with angiogenesis and malignant tumor growth. We designed an alphanubeta3-targeted nanoparticle (NP) encapsulating the cytotoxic drug doxorubicin (Dox) for targeted drug delivery to the alphanubeta3-expressing tumor vasculature. We observed real-time targeting of this NP to tumor vessels and noted selective apoptosis in regions of the alphanubeta3-expressing tumor vasculature. In clinically relevant pancreatic and renal cell orthotopic models of spontaneous metastasis, targeted delivery of Dox produced an antimetastatic effect. In fact, alphanubeta3-mediated delivery of this drug to the tumor vasculature resulted in a 15-fold increase in antimetastatic activity without producing drug-associated weight loss as observed with systemic administration of the free drug. These findings reveal that NP-based delivery of cytotoxic drugs to the alphanubeta3-positive tumor vasculature represents an approach for treating metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607000      PMCID: PMC2453735          DOI: 10.1073/pnas.0803728105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Drug delivery systems: entering the mainstream.

Authors:  Theresa M Allen; Pieter R Cullis
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

Review 2.  Cell integrins: commonly used receptors for diverse viral pathogens.

Authors:  Phoebe L Stewart; Glen R Nemerow
Journal:  Trends Microbiol       Date:  2007-11-07       Impact factor: 17.079

3.  Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment.

Authors:  T J Wickham; P Mathias; D A Cheresh; G R Nemerow
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

4.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

5.  Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer.

Authors:  Jan Grimm; Andreas Potthast; Andreas Wunder; Anna Moore
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

6.  Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins.

Authors:  M Pfaff; K Tangemann; B Müller; M Gurrath; G Müller; H Kessler; R Timpl; J Engel
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

7.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

Authors:  Fabio Pastorino; Chiara Brignole; Danilo Marimpietri; Michele Cilli; Claudio Gambini; Domenico Ribatti; Renato Longhi; Theresa M Allen; Angelo Corti; Mirco Ponzoni
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

8.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

Authors:  P C Brooks; S Strömblad; R Klemke; D Visscher; F H Sarkar; D A Cheresh
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

9.  Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging.

Authors:  Patrick M Winter; Shelton D Caruthers; Andrea Kassner; Thomas D Harris; Lori K Chinen; John S Allen; Elizabeth K Lacy; Huiying Zhang; J David Robertson; Samuel A Wickline; Gregory M Lanza
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

10.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.

Authors:  P C Brooks; A M Montgomery; M Rosenfeld; R A Reisfeld; T Hu; G Klier; D A Cheresh
Journal:  Cell       Date:  1994-12-30       Impact factor: 41.582

View more
  125 in total

Review 1.  Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

Authors:  William C Zamboni; Vladimir Torchilin; Anil K Patri; Jeff Hrkach; Stephen Stern; Robert Lee; Andre Nel; Nicholas J Panaro; Piotr Grodzinski
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

2.  Targeted nanogels: a versatile platform for drug delivery to tumors.

Authors:  Eric A Murphy; Bharat K Majeti; Rajesh Mukthavaram; Lisette M Acevedo; Leo A Barnes; David A Cheresh
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

Review 3.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

Review 4.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

Review 5.  Tumor ablation and nanotechnology.

Authors:  Rachel L Manthe; Susan P Foy; Nishanth Krishnamurthy; Blanka Sharma; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

6.  Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy.

Authors:  Ross I Berbeco; Alexandre Detappe; Panogiotis Tsiamas; David Parsons; Mammo Yewondwossen; James Robar
Journal:  Med Phys       Date:  2016-01       Impact factor: 4.071

7.  Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and Tumor Imaging.

Authors:  Lily Yang; Zehong Cao; Hari Krishna Sajja; Hui Mao; Liya Wang; Huaying Geng; Hengyi Xu; Tieshan Jiang; William C Wood; Shuming Nie; Y Andrew Wang
Journal:  J Biomed Nanotechnol       Date:  2008-12-01       Impact factor: 4.099

Review 8.  Tumor angiogenesis: molecular pathways and therapeutic targets.

Authors:  Sara M Weis; David A Cheresh
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

9.  Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes.

Authors:  Dandan Luo; Jumin Geng; Nasi Li; Kevin A Carter; Shuai Shao; G Ekin Atilla-Gokcumen; Jonathan F Lovell
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

10.  Cooperative nanomaterial system to sensitize, target, and treat tumors.

Authors:  Ji-Ho Park; Geoffrey von Maltzahn; Mary Jue Xu; Valentina Fogal; Venkata Ramana Kotamraju; Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.